Marzin Pauline, Cormier-Daire Valérie, Tsilou Ekaterini
Service de génétique clinique, Centre de référence pour les maladies osseuses constitutionnelles, Université de Paris, INSERM UMR1163, AP-HP, Institut Imagine, Hôpital Necker-Enfants malades, Paris, France
Medical Officer, General Medicine Branch 2, Division of Clinical Evaluation and Pharmacology/Toxicology, Office of Tissue and Advanced Therapies, Center for Biologics Evaluation and Research, United States Food and Drug Administration, Silver Spring, Maryland
Weill-Marchesani syndrome (WMS) is a connective tissue disorder characterized by abnormalities of the lens of the eye, short stature, brachydactyly, joint stiffness, and cardiovascular defects. The ocular problems, typically recognized in childhood, include microspherophakia (small spherical lens), myopia secondary to the abnormal shape of the lens, ectopia lentis (abnormal position of the lens), and glaucoma, which can lead to blindness. Height of adult males is 142-169 cm; height of adult females is 130-157 cm. Autosomal recessive WMS cannot be distinguished from autosomal dominant WMS by clinical findings alone.
DIAGNOSIS/TESTING: The diagnosis WMS is established in a proband with characteristic clinical features. Identification of biallelic pathogenic variants in , , or or of a heterozygous pathogenic variant in by molecular genetic testing can confirm the diagnosis if clinical features are inconclusive.
: Early detection and removal of an ectopic lens to decrease the possibility of pupillary block and glaucoma. Surgical management of glaucoma can include peripheral iridectomy to prevent or relieve pupillary block and trabeculectomy in advanced chronic angle closure glaucoma; medical treatment of glaucoma is difficult because of paradoxic response to miotics and mydriatics. Consider physical therapy for joint issues. Careful evaluation prior to anesthesia because of stiff joints, poorly aligned teeth, and maxillary hypoplasia. Treatment of cardiac anomalies per cardiologist. : Annual ophthalmology examinations for early detection and removal of an ectopic lens can help decrease the possibility of pupillary block and glaucoma. Annual assessment of height and joint range of motion. Regular cardiac follow up with echocardiogram and electrocardiography. : Ophthalmic miotics and mydriatics because they can induce pupillary block; activities that increase risk of eye injury.
-related WMS is inherited in an autosomal dominant manner. Most affected individuals have an affected parent. The proportion of individuals with autosomal dominant WMS caused by a pathogenic variant is unknown. Each child of an individual with autosomal dominant WMS has a 50% chance of inheriting the pathogenic variant. , , and -related WMS are inherited in an autosomal recessive manner. The parents of an affected individual are obligate heterozygotes (i.e., presumed to be carriers of one pathogenic variant based on family history). If both parents are known to be heterozygous for a pathogenic variant, each sib of an affected individual has at conception a 25% chance of being affected, a 50% chance of being an asymptomatic carrier, and a 25% chance of being unaffected and not a carrier. Carrier testing of at-risk relatives is possible if the WMS-related pathogenic variants have been identified in the family. Prenatal and preimplantation genetic testing are possible once the WMS-related pathogenic variant(s) have been identified in an affected family member.
Weill-Marchesani综合征(WMS)是一种结缔组织疾病,其特征为眼部晶状体异常、身材矮小、短指畸形、关节僵硬和心血管缺陷。眼部问题通常在儿童期被发现,包括小晶状体(小球形晶状体)、因晶状体异常形状继发的近视、晶状体异位(晶状体位置异常)和青光眼,后者可导致失明。成年男性身高为142 - 169厘米;成年女性身高为130 - 157厘米。仅通过临床检查结果无法区分常染色体隐性遗传的WMS和常染色体显性遗传的WMS。
诊断/检测:具有特征性临床特征的先证者可确诊为WMS。如果临床特征不明确,通过分子遗传学检测鉴定出 、 或 中的双等位基因致病变异或 中的杂合致病变异可确诊。
早期发现并摘除异位晶状体以降低瞳孔阻滞和青光眼的发生可能性。青光眼的手术治疗可包括周边虹膜切除术以预防或缓解瞳孔阻滞,以及晚期慢性闭角型青光眼的小梁切除术;由于对缩瞳剂和散瞳剂有反常反应,青光眼的药物治疗较为困难。考虑针对关节问题进行物理治疗。由于关节僵硬、牙齿排列不齐和上颌发育不全,麻醉前需仔细评估。心脏异常由心脏病专家进行治疗。每年进行眼科检查以早期发现并摘除异位晶状体,有助于降低瞳孔阻滞和青光眼的发生可能性。每年评估身高和关节活动范围。定期通过超声心动图和心电图进行心脏随访。避免使用眼科缩瞳剂和散瞳剂,因为它们可诱发瞳孔阻滞;避免增加眼部受伤风险的活动。
与 相关的WMS以常染色体显性方式遗传。大多数受影响个体有一位患病父母。由 致病变异引起的常染色体显性WMS个体所占比例未知。常染色体显性WMS个体的每个孩子有50%的几率遗传该致病变异。与 、 和 相关的WMS以常染色体隐性方式遗传。受影响个体的父母为 obligate杂合子(即根据家族史推测为一个致病变异的携带者)。如果已知父母双方均为一个致病变异的杂合子,受影响个体的每个同胞在受孕时有25%的几率患病,50%的几率为无症状携带者,25%的几率未患病且不是携带者。如果在家族中已鉴定出与WMS相关的致病变异,可对有风险的亲属进行携带者检测。一旦在受影响家庭成员中鉴定出与WMS相关的致病变异,即可进行产前和植入前基因检测。